Date: 20 Aug 2019
Picture Credits: Newcastle University
HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.
- A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients.
- Incorporating several new partners also enables access to even more state-of-the art technologies.
- HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.
Date: 07 Aug 2019
Picture Credits: Enterprise Singapore
In a cross-border collaboration, HistoIndex and the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, India have jointly launched a Centre of Excellence (CoE) to aid diagnostics and clinical trials focusing on NASH. The CoE is HistoIndex's first Genesis Imaging Service (GIS) partner in India and joins the company's global network of medical, academic and referral laboratory partners who are involved in comprehensive clinical and scientific studies on NASH and other chronic liver conditions.Read More
Date: 23 Dec 2018
HistoIndex's AI-based SHG technology has the potential to yield important results from NASH clinical trials. HistoIndex's SHG technology was featured in Madrigal Pharmaceuticals' Presidential Plenary presentation during AASLD's The Liver Meeting® 2018, for its presentation entitled, "In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy".Read More
Date: 06 Jul 2018
HistoIndex has appointed Dr Poon Thong Yuen as its new Chief Executive Officer (CEO) with effect from 1 July 2018. Dr Poon takes over from Dr Gideon Ho, who will continue to drive the global business growth of the company as the Chief Commercial Officer (CCO).
Says Dr Poon, “Providing clinical trial services to the biopharma industry is the first step for us to work closely with pharmaceutical companies that are developing drugs for NASH. Our eventual goal is to be a Companion Diagnostics platform for NASH.”Read More
Date: 08 Jun 2018
As part of the international NASH Education Program™, HistoIndex has joined over 150 world experts in a global call of action to promote the awareness of NASH in Singapore.Read More
Date: 18 May 2018
Histoindex Pte. Ltd., with the world’s first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH).Read More
Date: 11 Jan 2018
The stain-free Laennec® digital pathology imaging system by HistoIndex® has achieved its first regulated in vitro diagnostics (IVD) product status with the issuance of a Health Sciences Authority (HSA) Class A licence. This is a world’s first achievement for a stain-free digital pathology innovation to be approved for use in a clinical diagnosis setting.Read More
Date: 04 Oct 2017
Histoindex Pte. Ltd. has been presented with the 2017 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics New Product Innovation Award by Frost & Sullivan. The award is a testament of the achievements by HistoIndex and the impact of its proprietary technologies such as Genesis®200 on aiding clinical diagnosis and the development of NASH therapeutics.Read More
Date: 13 Jan 2016
China-based Qingdao Yaozhu has entered into a joint venture agreement to co-invest with Singapore-headquartered medtech company, HistoIndex®.Read More